PDCD1 and non-small cell lung carcinoma: Surprisingly, several clinical trials reveal that the survival benefits for NSCLC patients from anti-PD1/PD-L1 immunotherapy is independent of PD-L1 expression (18–23), thus the true predictive value of PD-L1 is limited (24).